Zymeworks Inc.
NYSE:ZYME
12.52 (USD) • At close September 18, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Zymeworks Inc. |
Symbool | ZYME |
Munteenheid | USD |
Prijs | 12.52 |
Beurswaarde | 889,513,448 |
Dividendpercentage | 0% |
52-weken bereik | 6.015 - 13.14 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Kenneth H. Galbraith C.A. |
Website | https://www.zymeworks.com |
An error occurred while fetching data.
Over Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)